sevelamer (renagel) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel and Renvela.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1154 - $13.5483

Australia

$0.9206
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

gt16-026a | gt335-012 | renagel | renvela | sevelamer | sévélamer | sevelamer carbonate | sevelamer hcl | sevelamer hydrochloride | sevelamero | sevelamerum

Organizations (113)

Research & Development (88)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (2)


 

Kidney Diseases

Renal Insufficiency, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Arteriosclerosis (Phase 4)

Calcinosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 3)

Diabetic Nephropathies (Phase 2)

Dialysis (Phase 3)

Endothelium (Phase 4)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperparathyroidism (Phase 3)

Hyperparathyroidism, Secondary (Phase 4)

Hyperphosphatemia (Phase 4)

Insulin Resistance (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Peritoneal Dialysis (Phase 3)

Renal Dialysis (Phase 4)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic ()

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 79
  • # of Trial Organizations: 88

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue